Alnylam Q1 product rev $276M (+48% YoY); ALN-APP CNS data positive; FY guidance reaffirmed

ALNYLAM PHARMACEUTICALS, INC.

2023-Q1 EPS reported -$1.40 revenue$319,290,000

Q1 net product revenue $276M (+48% YoY); AMVUTTRA $102M and ONPATTRO $102M drove TTR growth of 49%.
GAAP net loss $174M ($1.40/share); non-GAAP net loss $132M ($1.06/share). FY23 revenue guidance $1.2B-$1.285B reaffirmed.
Positive interim Phase 1 data for ALN-APP in early-onset Alzheimer's: first human RNAi CNS gene silencing demonstrated.
18-month APOLLO-B data submitted to FDA for ONPATTRO in cardiomyopathy; KARDIA-1 (zilebesiran) topline expected mid-2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ALNYLAM PHARMACEUTICALS, INC. reported the first quarter ended March 31, 2023 results: revenue $276 Million. Guidance reaffirmed.

Period: the first quarter ended March 31, 2023
Revenue: $276 Million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

− Achieved First Quarter 2023 Global Net Product Revenues of $276 Million, Representing 48% Year-Over-Year Growth Compared to Q1 2022 –

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

ALNYLAM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001157523-23-000728

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.